RefleXion
25841 Industrial Blvd
#275
Hayward
California
94545
United States
Fax: (650) 239-9070
Website: http://www.reflexion.com/
Email: contact@reflexion.com
About RefleXion
RefleXion is a privately held therapeutic oncology company located in Hayward, Calif., transforming radiopharmaceuticals from diagnosing cancer to actively controlling delivery of external-beam radiotherapy by leveraging individual tumor biology. Designated an FDA Breakthrough Device, RefleXion’s SCINTIX™ biology-guided radiotherapy automates targeting and motion management to overcome long-standing barriers preventing definitive radiotherapy for metastatic disease. In strategic collaborations with radiopharmaceutical companies, RefleXion is co-developing and co-commercializing disease-specific radiopharmaceuticals for difficult to treat late-stage cancers. RefleXion’s vision is to extend the established safety, efficacy and cost-effectiveness of external-beam radiotherapy to patients with solid tumor malignancies of any stage.
CONNECT
The RefleXion® X1 with SCINTIX™ technology marries PET and CT, proven modalities for visualizing cancer, with radiotherapy, one of the most effective ways of treating cancer, in a dual-treatment modality platform.
31 articles about RefleXion
-
RefleXion Announces Installation of X1 Platform at Smilow Cancer Hospital at Yale New Haven
3/1/2023
RefleXion Medical, Inc., a therapeutic oncology company, announced the installation of its RefleXion® X1 platform at Smilow Cancer Hospital, part of Yale New Haven Health, Connecticut’s largest healthcare system.
-
RefleXion Highlights New Cancer Treatment Research Abstracts for Presentation at ASTRO 2022
10/20/2022
RefleXion® Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced eight clinical abstracts evaluating the potential use and utility of its novel technology were accepted for presentation during the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting, Oct. 23-26, in San Antonio.
-
RefleXion Announces 14 Medical Physics Investigations at 2022 AAPM Annual Meeting
7/11/2022
Oral presentation evaluating feasibility of BgRT using long-lived immune PET tracer awarded Best in Physics.
-
RefleXion Announces Licensing Agreement with Mirada Medical to Advance Personalized Cancer Treatment
7/7/2022
RefleXion Medical , a therapeutic oncology company pioneering the use of biology-guided radiotherapy ( BgRT )* for all stages of cancer, today announced a non-exclusive, worldwide licensing agreement with Mirada Medical.
-
RefleXion Announces Closing of $125M Debt Facility for Expanding Cancer Treatment
7/6/2022
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy * for all stages of cancer, announced the closing of a $125M debt facility, of which $55M is available immediately to repay the company’s existing $50M of debt.
-
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
6/10/2022
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. ( Hayward, California , U.S.) (RefleXion) today announced the signing of a co-development and commercialisation agreement, to expand the use of Telix's prostate cancer imaging agent, Illuccix ®.
-
RefleXion Announces Real-World Evidence Outcomes Registry to Evaluate Treatment Impact on all Stages of Cancer
5/3/2022
RefleXion Medical announced the enrollment of the first patient into its PREMIER registry, a prospective, real-world evidence clinical outcomes registry for patients with all stages of cancer, at the University of Texas Southwestern in Dallas.
-
Money on the Move: March 9-15
3/16/2022
The companies that got money this week were the ones investing in ambitious, future-looking technologies, such as RNA genomics, biochips and antibody-drug conjugates. -
Two oncology-focused biotechnology firms generated a total of $247 million in additional funding to support their respective research and development efforts for cancer treatment.
-
RefleXion Raises $80 Million to Broaden Cancer Treatment Options
3/10/2022
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy * for all stages of cancer, announced the close of an $80 million equity financing.
-
RefleXion Receives Breakthrough Device Designation for Lung Cancer Treatment
12/1/2021
RefleXion Medical, Inc., a therapeutic oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its biology-guided radiotherapy* (BgRT) for use in treating lung tumors.
-
RefleXion Highlights New Cancer Treatment Research at ASTRO 2021
10/21/2021
RefleXion Medical, today announced multiple clinical abstracts evaluating the potential use and utility of its novel technology were accepted for presentation during the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, Oct. 24-27, in Chicago.
-
RefleXion Announces Newly Formed Scientific Advisory Board
10/19/2021
RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* as a new modality for treating all stages of cancer, announced the formation of a 10-member Scientific Advisory Board.
-
RefleXion Expands Commercial Reach With Sale to Texas Cancer Center
7/21/2021
RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy* as a new modality that will one day treat all stages of cancer, announced the sale of its RefleXion™ X1 machine to The Center for Cancer and Blood Disorders, a free-standing cancer treatment center with 15 locations throughout northern Texas.
-
RefleXion Announces New Additions to Board of Directors and Appoints Audit Committee Chair
5/27/2021
RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced the appointment of three external directors to its board of directors, Renee Ryan, Rana Al-Hallaq, Ph.D., and Alice Schroeder
-
RefleXion Adds Ally Bridge Group to Investor Syndicate
3/2/2021
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy * for all stages of cancer, announced the successful completion of a $40 million extension to its Series D financing, which combined with $110 million raised in 2020, brings the total Series D financing to $150 million.
-
RefleXion and HealthMyne Collaborate to Use Patient's Tumor Data to Guide Cancer Therapy
1/7/2021
RefleXion Medical , a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, and HealthMyne Inc ., an inno
-
RefleXion Announces Multi System Agreement With Integrated Proton Solutions
11/16/2020
Free Standing Centers Improve Accessibility to Sophisticated Cancer Care for Local Communities
-
RefleXion and Telix Pharmaceuticals Announce Strategic Collaboration for Treatment of High-Risk Cancers
7/8/2020
RefleXion Medical , a therapeutic oncology company pioneering biology-guided radiotherapy* ( BgRT ) as a new modality for treating all stages of cancer, and Telix Pharmaceuticals Limited (ASX: TLX), a radiopharmaceutical company developing molecularly-targeted radiation ( MTR ) products, today announced a strategic collaboration to investigate the clinical utility of combining the companies’
-
RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck’s KEYTRUDA® for Certain Late-Stage Cancers
5/28/2020
RefleXion Medical , a therapeutic oncology company pioneering biology-guided radiotherapy* ( BgRT ) for treating all stages of cancer, today announced a clinical collaboration with Merck (known as MSD outside the U.S. and Canada) to evaluate the safety and efficacy of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with BgRT in multiple late-stage cancers, including non-small cell lung cancer (NSCLC)